Cetuximab versus bevacizumab in metastatic colorectal cancer: a comparative effectiveness study.

CONCLUSION: This study provides evidence suggesting bevacizumab and cetuximab lead to similar effectiveness outcomes in mCRC, except for right-sided tumours, where cetuximab seemed to show considerably poorer outcomes. Further research is needed to confirm these results. PMID: 32144533 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/32144533?dopt=Abstract

Source: Clinical Colorectal Cancer - March 5, 2020 Category: Cancer & Oncology Authors: Marques RP, Godinho AR, Heudtlass P, Pais HL, Quintela A, Martins AP Tags: J Cancer Res Clin Oncol Source Type: research